PDLBHIGH SIGNALREGULATORY10-K

Ponce Bank completed a significant regulatory transformation from a federally chartered stock savings association to a national bank, accompanied by exceptional financial performance improvements.

The charter conversion to national bank status represents a major strategic milestone that typically provides expanded regulatory flexibility and operational capabilities. This regulatory upgrade, combined with the dramatic financial improvements, suggests successful execution of a significant business transformation that could enhance the company's competitive positioning and growth prospects.

Comparing 2026-03-13 vs 2025-03-13View on EDGAR →
FINANCIAL ANALYSIS

The company delivered exceptional financial performance with net income surging 162% to $28.7M and operating cash flow exploding 671% to $55.6M, indicating dramatically improved operational efficiency and profitability. Net interest income grew a solid 14% to $185.5M while the company increased share buybacks significantly to $11.0M, demonstrating strong capital generation and shareholder-friendly capital allocation. The substantial reduction in capital expenditures alongside massive cash flow improvement suggests the business has reached a more mature, cash-generative phase following its regulatory transformation.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+670.9%
$7.2M$55.6M

Operating cash flow surged 670.9% — exceptional cash generation, highest quality earnings signal.

Share Buybacks
Cash Flow
+585.1%
$1.6M$11.0M

Share repurchases increased 585.1% — management returning capital, signals confidence in intrinsic value.

Net Income
P&L
+161.6%
$11.0M$28.7M

Net income grew 161.6% — bottom-line growth signals improving overall business health.

Provision for Credit Losses
P&L
+81.9%
$535K$973K

Credit loss provisions surged 81.9% — management flagging significant deterioration in loan quality ahead.

Capital Expenditure
Cash Flow
-64%
$2.7M$978K

Capex reduced 64% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Net Interest Income
P&L
+14.1%
$162.6M$185.5M

Net interest income grew 14.1% — benefiting from rate environment or loan book expansion.

LANGUAGE CHANGES
NEW — 2026-03-13
PRIOR — 2025-03-13
ADDED
As of March 11, 2026, the registrant had 24,156,831 shares of com mon stock, $0.01par value per share, outstanding.
Forward-looking statements speak only as of the date they are made.
The Company is under no duty to and does not assume any obligation to update any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise, except as required by law.
(hereafter referred to as we, our, us, Ponce Financial Group, Inc., or the Company ), is a financial holding company and the holding company of Ponce Bank, National Association ( Ponce Bank or the Bank ), a national bank.
Ponce Bank Ponce Bank is a national bank headquartered in the Bronx, New York.
+7 more — sign up free →
REMOVED
As of March 12, 2025, the registrant had 23,966,191 shares of common stock, $0.01par value per share, outstanding.
The Company is under no duty to and does not assume any obligation to update any forward-looking statements after the date they are made, whether as a result of new information, future events or otherwise.
(hereafter referred to as we, our, us, Ponce Financial Group, Inc., or the Company ), is the holding company of Ponce Bank ( Ponce Bank or the Bank ), a federally chartered stock savings association.
Ponce Bank Ponce Bank is a federally-chartered stock savings association headquartered in the Bronx, New York.
The assets and liabilities of Ponce De Leon Federal Bank were transferred to and assumed by the Bank.
+7 more — sign up free →
MORE REGULATORY SIGNALS
BCHTHIGHBCHT has added extensive PFAS chemical definitions to their 10-K while removing ...
2026-03-31
OMERHIGHOMER achieved FDA approval for YARTEMLEA in December 2025, transforming from a c...
2026-03-31
UNCYHIGHThe FDA issued a Complete Response Letter (CRL) in June 2025 rejecting UNCY's dr...
2026-03-30
NVNOHIGHNVNO received a not-approvable letter from the FDA for its lead product VenoValv...
2026-03-26
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →